Sarcosine as a potential prostate cancer biomarker and therapeutic target

Cancer Biology and Therapy

Volumn 9, Issue 5, 2010, Pages 341-342

  Baum, Caitlin E ^a   Price, Douglas K ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarker; Metastasis; Prostate cancer; PSA; Sarcosine

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; HISTONE LYSINE METHYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; SARCOSINE;

CANCER INVASION; DIAGNOSTIC VALUE; ENZYME ACTIVITY; HUMAN; METABOLITE; NOTE; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION;

HUMANS; MALE; PROSTATIC NEOPLASMS; SARCOSINE; TUMOR MARKERS, BIOLOGICAL;

EID: 77953704046     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.5.11310     Document Type: Note

References (7)

1. Halpern EJ. Contrast-enhanced ultrasound imaging of prostate cancer. Rev Urol 2006; 8:29-37.
2. Fuchsjager M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. Prostate cancer imaging. Acta Radiol 2008; 49:107-20.
3. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nat Lett 2009; 457:6.
4. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8:11.
5. Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer-the post PSA era. Anticancer Res 2009; 29:3289-98.
6. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644-8.
7. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9.